6.86

18.69% 1.08

After Hours: 6.89 0.03 +0.44%

Voyager Therapeutics Inc (VYGR)

Overview News Price History Option Chain Financials Discussions Forecast

Voyager Therapeutics Inc stock is traded at $6.86, with a volume of 1.19M. It is up +18.69% in the last 24 hours and down -2.97% over the past month. Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Previous Close:

$5.78

Open:

$6.27

24h Volume:

1.19M

Relative Volume:

2.11

Market Cap:

$374.73M

Revenue:

$163.78M

Net Income/Loss:

$25.88M

P/E Ratio:

3.022

EPS:

2.27

Net Cash Flow:

$-28.66M

1W Performance:

+21.31%

1M Performance:

-2.97%

6M Performance:

-12.28%

1Y Performance:

-2.42%

1-Day Range:

$6.266

$7.03

1-Week Range:

$5.54

$7.03

52-Week Range:

$5.19

$11.72

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name

Voyager Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

857-259-5340

Address

75 HAYDEN AVENUE, LEXINGTON, MA

Employee

162

Twitter

@VoyagerTx

Next Earnings Date

2024-11-04

Latest SEC Filings

VYGR's Discussions on Twitter

Compare VYGR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VYGR Voyager Therapeutics Inc	6.86	374.73M	163.78M	25.88M	-28.66M	0.65
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-24	Initiated	Leerink Partners	Outperform
Mar-26-24	Initiated	Guggenheim	Buy
Mar-19-24	Initiated	H.C. Wainwright	Buy
Mar-07-24	Initiated	Citigroup	Buy
Jan-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
May-10-23	Initiated	Truist	Buy
Mar-10-23	Initiated	Oppenheimer	Outperform
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-19-20	Initiated	The Benchmark Company	Buy
Feb-06-20	Initiated	Oppenheimer	Outperform
Nov-15-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-10-18	Resumed	BTIG Research	Buy
Sep-10-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-04-18	Initiated	H.C. Wainwright	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Mar-12-18	Downgrade	Wedbush	Outperform → Neutral
Feb-02-18	Initiated	Morgan Stanley	Overweight
Nov-28-17	Resumed	Piper Jaffray	Overweight
Oct-31-17	Initiated	Robert W. Baird	Outperform
Oct-27-17	Initiated	Canaccord Genuity	Buy
Oct-23-17	Reiterated	Stifel	Buy
Oct-12-17	Initiated	Raymond James	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-28-17	Resumed	Stifel	Buy

View All

Voyager Therapeutics Inc Stock (VYGR) Latest News

09:45 AM

Voyager Therapeutics (NASDAQ:VYGR) Earns Outperform Rating from Analysts at Wedbush - MarketBeat

09:45 AM

06:55 AM

Wedbush upgrades Voyager to Outperform on pipeline progress - Yahoo Finance

06:55 AM

Nov 29, 2024

Wedbush assumes coverage of Voyager with outperform rating - MSN

Nov 29, 2024

Wedbush assumes coverage of Voyager with outperform rating (NASDAQ:VYGR) - Seeking Alpha

Nov 29, 2024

Vestal Point Capital LP Sells 110,000 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - MarketBeat

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail

Nov 29, 2024

Nov 27, 2024

Great Point Partners LLC Lowers Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - MarketBeat

Nov 27, 2024

Nov 26, 2024

Empowered Funds LLC Increases Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World

Nov 26, 2024

Nov 22, 2024

Voyager Therapeutics Inc earnings beat by $0.29, revenue topped estimates - Investing.com Nigeria

Nov 22, 2024

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $17.00 Consensus Target Price from Analysts - MarketBeat

Nov 22, 2024

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Nov 22, 2024

Nov 21, 2024

Voyager Therapeutics to advance tau silencing gene therapy for Alzheimer’s disease - BioWorld Online

Nov 21, 2024

Nov 20, 2024

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease - GlobeNewswire

Nov 20, 2024

Voyager's New Alzheimer's Gene Therapy Shows 73% Tau Reduction in Key Study | VYGR Stock News - StockTitan

Nov 20, 2024

Nov 18, 2024

Voyager Therapeutics’ TRACER Platform Targets CNS Market: Here’s Why I’m Neutral (VYGR) - Seeking Alpha

Nov 18, 2024

Voyager Therapeutics (NASDAQ:VYGR) Rating Increased to Buy at StockNews.com - MarketBeat

Nov 18, 2024

FY2024 Earnings Forecast for VYGR Issued By HC Wainwright - MarketBeat

Nov 18, 2024

Nov 17, 2024

Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at Canaccord Genuity Group - Defense World

Nov 17, 2024

Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 17, 2024

Nov 15, 2024

Voyager Therapeutics' (VYGR) Buy Rating Reaffirmed at Canaccord Genuity Group - MarketBeat

Nov 14, 2024

Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

Nov 14, 2024

Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 14, 2024

Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)? - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Earnings call: Voyager Therapeutics focuses on neurological therapies By Investing.com - Investing.com Canada

Nov 13, 2024

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Voyager Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 13, 2024